Exemestane-d4

Exemestane-d4 (FCE 24304-d4) is deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

Product Specifications

Product Name Alternative

FCE 24304-d4; EXE-d4

UNSPSC

12352211

Target

Cytochrome P450; Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Endocrinology

Smiles

C[C@@]12[C@]3([H])[C@](C/C(C1=CC(C=C2)=O)=C([2H])/[2H])([H])[C@@]4([H])[C@](CC3)(C(C([2H])([2H])C4)=O)C

Molecular Formula

C20H20D4O2

Molecular Weight

300.43

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Di Salle, E., et al., Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol, 1994. 49 (4-6) : p. 289-94.|[3]Miki, Y, et al. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2004 Sep 1;10 (17) :5717-23.|[4]Goss, P.E., et al., Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res, 2004. 10 (17) : p. 5717-23.|[5]Zaccheo, T., D. Giudici, and E. Di Salle, Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol, 1993. 44 (4-6) : p. 677-80.